Crispr Therapeutics (NASDAQ:CRSP) had its price objective upped by equities research analysts at Goldman Sachs Group from $52.00 to $75.00 in a research report issued to clients and investors on Tuesday, November 19th, The Fly reports. The firm currently has a “neutral” rating on the stock. Goldman Sachs Group’s price target would suggest a potential upside of 4.68% from the company’s current price.
CRSP has been the subject of a number of other research reports. BidaskClub upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 15th. Barclays upped their price objective on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Roth Capital upped their price objective on shares of Crispr Therapeutics from $50.00 to $65.00 in a research report on Tuesday, July 30th. Piper Jaffray Companies reiterated an “overweight” rating on shares of Crispr Therapeutics in a report on Monday, October 21st. Finally, Oppenheimer upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating and set a $65.00 price target for the company in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $69.54.
Shares of Crispr Therapeutics stock opened at $71.65 on Tuesday. The company has a fifty day simple moving average of $49.98 and a 200-day simple moving average of $46.23. Crispr Therapeutics has a 12-month low of $22.22 and a 12-month high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of -20.83 and a beta of 3.15.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at $412,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock valued at $3,620,760 over the last 90 days. Company insiders own 21.40% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Nikko Asset Management Americas Inc. grew its position in Crispr Therapeutics by 48.4% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares during the last quarter. ARK Investment Management LLC lifted its holdings in shares of Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after purchasing an additional 701,332 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Finally, Orbimed Advisors LLC bought a new position in shares of Crispr Therapeutics in the 3rd quarter worth $21,167,000. Institutional investors and hedge funds own 49.81% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What is a Roth IRA?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.